Navigation Links
New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law

ARLINGTON, Va., Jan. 3, 2011 /PRNewswire-USNewswire/ -- BNA Books, a division of BNA, announces the publication of the Second Edition of Pharmaceutical Patent Law, the most relied upon reference available with a detailed, practitioner-oriented treatment of pharmaceutical patent law from the perspective of both patent law and the food and drug laws.


This revised treatise takes on the complicated tasks of tracking legal developments within the PTO, FDA, Congress, the courts, the FTC, the Department of Justice, and the WTO. This treatise examines how these agencies and organizations interact with each other and analyzes how they will impact strategies within a practitioner's core area of expertise.

Pharmaceutical Patent Law, Second Edition provides complete coverage of advanced topics, including the antitrust implications of patent settlements, the experimental use privilege, and international aspects of the field. Core topics covered include:

  • The substance and procedure of pharmaceutical patent acquisition
  • FDA marketing approval procedures for innovative and generic drugs
  • The FDA's Orange Book
  • Patent term extension standards
  • FDA marketing exclusivities
  • The scope of patent rights
  • Patent infringement procedures under the Hatch-Waxman Act
  • Defenses to patent infringement
  • Remedies for patent infringement
  • The experimental use privilege
  • Antitrust treatment of pharmaceutical patent settlements
  • International aspects of pharmaceutical patent practice

The Second Edition includes the following new information:

  • Extensive coverage of the new follow-on biologics statute
  • The impact of Bilski v. Kappos on diagnostic method claims
  • New judicial guidance on patent term extensions under the Hatch-Waxman Act
  • Significant case law regarding forfeiture of the 180-day generic exclusivity
  • The developing law of "obvious to try" in the post-KSR era

Pharmaceutical Patent Law, Second Edition not only reviews current issues of importance, but identifies topics such as parallel importation and authorized generics that are likely to be of growing significance. The author, Professor John R. Thomas, is a member of the faculty of Georgetown University Law Center, Washington, DC, where he teaches courses in both patent and food and drug law.

BNA is a leading private publisher of news and information products for professionals in law and business. In addition to Pharmaceutical Patent Law, BNA's Book Division publishes Anatomy of a Patent Case;  Biotechnology and the Federal Circuit; Constructing and Deconstructing Patents; Drafting Patent License Agreements; Electronic and Software Patents: Law and Practice; Intellectual Property Taxation: Transaction and Litigation Issues; International Patent Litigation: A Country-by-Country Analysis; Patent Infringement Remedies; Patent Law and Practice; Patent Prosecution: Law, Practice, and Procedure; Patent, Trademark, and Copyright Laws; Patent, Trademark, and Copyright Regulations; Patents and the Federal Circuit; Trademark Litigation Practice; Harmon on Patents: Black-Letter Law and Commentary; and other titles in legal specialties. The BNA Books website, including an online catalog, can be found at

The new Second Edition of Pharmaceutical Patent Law may be purchased (860 pp. Hardcover/Order #1898-PREL10/$445.00 plus tax, shipping, and handling) from BNA Books, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1-800-960-1220. Fax orders: 1-732-346-1624. For a free BNA Books catalog, call 1-800-960-1220 or send an e-mail request to A 10% discount is available on print copies of books when ordered from the website at (Please note that discounts cannot be combined).

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any ... opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with the ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... Karnataka (PRWEB) , ... November 27, 2015 , ... ... world, Health-E-minds, an innovative online platform for mental health and wellness consultation, has ... , This partnership will bridge the knowledge gap experienced by parents and bring ...
Breaking Medicine News(10 mins):